News Related to NATCO Pharma Ltd.

Related coverage linked through entity extraction aliases.

Natco Pharma Shares Surge 11% on Approval to Launch Generic Semaglutide in India

Feb 16, 2026

Natco Pharma received CDSCO approval to manufacture and launch generic semaglutide injection in India next month for type 2 diabetes treatment, sending shares up over 11% on Monday.

Natco Pharma Receives Approval for Generic Semaglutide in India, Launch Planned for March

Feb 13, 2026

Natco Pharma has received approval from India's CDSCO to manufacture and market generic semaglutide injection, with a March 2026 launch planned. The approval comes amid patent litigation and intense competition in India's rapidly expanding diabetes and obesity drug market.